Albireo Pharma (ALBO) Reports FY16 Loss of $13.16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Albireo Reports 2016 Financial Results
March 14, 2017 7:30 AM EDTPromising Phase 2 data for A4250 in pediatric cholestatic liver disease
Initiation of A4250 Phase 3 trial planned for 2H 2017
JNDA filing for elobixibat by licensee EA Pharma
Consummation of business combination to become NASDAQ listed
Conference call today at 8:30 a.m. ET
BOSTON, March 14, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ: ALBO), an orphan pediatric liver disease company developing novel bile acid modulators, today... More
